| P2093 | author name string | Andrew Miller | |
| | Kavitha Subramaniam | |
| | Paul Pavli | |
| | Faseeha C Peer | |
| P2860 | cites work | Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. | Q36402885 |
| | Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions | Q36740090 |
| | Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients | Q37037622 |
| | Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease | Q37390797 |
| | Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review | Q37560336 |
| | Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect | Q37859958 |
| | Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature | Q37940516 |
| | Skin side effects of inflammatory bowel disease therapy | Q38087852 |
| | Infliximab-induced skin manifestations in patients with inflammatory bowel disease | Q40148140 |
| | Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease | Q40792685 |
| | Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience | Q41098795 |
| | Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. | Q41520678 |
| | Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case | Q43248947 |
| | The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study | Q43452900 |
| | The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series | Q44750951 |
| | Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy | Q44771716 |
| | Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system | Q45062333 |
| | Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. | Q50986864 |
| | Psoriasis induced by infliximab in a patient suffering from Crohn's disease. | Q51610121 |
| | Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis | Q57306861 |
| P433 | issue | 12 | |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| | TNF | Q18032037 |
| P304 | page(s) | 1445-1448 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Internal Medicine Journal | Q15749165 |
| P1476 | title | Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients | |
| P478 | volume | 47 | |